AveXis’s New Gene Therapy Approved but New Questions Are Raised
The United States Food and Drug Administration released a statement regarding a recently approved gene therapy drug, Zolgensma, intended to treat children less than two years of age with spinal muscular atrophy. It is a critical therapy meeting an unmet need. However, the FDA was informed that the manufacturer, AveXis Inc., a subsidiary of Novartis, […]